Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?

Alex Renner, Mauricio Burotto, Jose Miguel Valdes, Juan Carlos Roman, Annerleim Walton-Diaz

Research output: Contribution to journalReview articlepeer-review

Abstract

Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI agents in the first- and second-line settings. This has led to an increased interest in studying their efficacy in the neoadjuvant setting for muscle invasive disease – an area of significant unmet need. This non-systematic review will look at the evidence supporting the use of ICI in the neoadjuvant setting for this tumor, results of early-phase studies, ongoing trials, and possible future applications for these drugs.

Original languageEnglish
JournalTherapeutic Advances in Urology
Volume13
DOIs
StatePublished - 2021

Bibliographical note

Publisher Copyright:
© The Author(s), 2021.

Keywords

  • bladder cancer
  • immune checkpoint inhibitor
  • immunotherapy
  • muscle invasive
  • neoadjuvant

Fingerprint

Dive into the research topics of 'Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?'. Together they form a unique fingerprint.

Cite this